<DOC>
	<DOCNO>NCT00735215</DOCNO>
	<brief_summary>The sequential administration endocrine therapies patient advance breast cancer require availability therapy different mode action , tumour develop resistance one agent cross resistant another . Because mechanism action , fulvestrant distinct hormonal therapy , therefore limit possibility cross-resistance therapy tamoxifen aromatase inhibitor ( AIs ) - In way , patient may benefit extended period endocrine treatment , considerable tolerability quality-of-life advantage cytotoxic chemotherapy . - In Belgium , fulvestrant indicate treat postmenopausal woman hormone receptor-positive locally advanced metastatic breast cancer recurrence adjuvant anti-oestrogen therapy disease progression anti-oestrogen treatment . However , little information currently available fulvestrant actually use physician Belgium . The optimum sequence endocrine treatment advance breast cancer yet define may depend certain patient disease characteristic . Fulvestrant grant reimbursement Belgian Health authority ( RIZIV/INAMI ) recommendation collect real life data necessary ass patient ' breast cancer treatment history may influence actual endocrine treatment sequence accord physician current clinical practice..</brief_summary>
	<brief_title>Faslodex Registry : Fulvestrant Current Clinical Practice</brief_title>
	<detailed_description />
	<mesh_term>Fulvestrant</mesh_term>
	<criteria>Postmenopausal woman hormone receptorpositive locally advanced metastatic breast cancer</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Breast cancer ,</keyword>
	<keyword>fulvestrant ,</keyword>
	<keyword>postmenopausal ,</keyword>
	<keyword>woman</keyword>
	<keyword>locally advanced ,</keyword>
	<keyword>hormone receptor-positive .</keyword>
</DOC>